NEW YORK, June 27, 2026, 11:04 (EDT)
- Generate Biomedicines, Inc. NASDAQ:GENB closed Friday at $16.47, above its $16 IPO price, and was quoted at $16.95 after hours.
- The stock gained 13.7% from the June 18 close through Friday and logged three straight closes above $16, based on daily price data.
- Friday volume was 4.10 million shares, about 4.4 times average volume; Nasdaq is shut this weekend and will close again Friday, July 3, for Independence Day observed.
Generate Biomedicines, Inc. NASDAQ:GENB ended a short U.S. trading week back over its IPO price, a sharper test for investors than the 0.3% Friday close suggests. The shares closed at $16.47, touched a 52-week high of $17.42 this week and traded 4.10 million shares Friday against average volume of 934,290.
From the June 18 close of $14.49, the last close before the Juneteenth market holiday, through Friday’s close, GENB rose 13.7%. It closed above $16 on Wednesday, Thursday and Friday, after closing at $15.89 on Monday and $15.43 on Tuesday.
That matters because the $16 line is not just a chart mark. Generate raised $400 million at $16 a share in February, opened at $15 in its Nasdaq debut and was valued at $1.91 billion at the open, Reuters reported.
At Friday’s close, Generate’s market value was about $2.11 billion. Its March 31 cash, cash equivalents and marketable securities stood at $516.6 million, or about $4.03 per share using the 128.2 million shares outstanding in its 10-Q. At first-quarter operating cash use of $80.4 million, that cash pile equaled about 6.4 quarters if spending stayed flat. The company said the cash can fund current operating plans into the first half of 2028, but it also said it expects to need more capital for long-term operations.
The clinical risk sits next to that cash math. Generate’s 10-Q said FDA and EMA recommended a dose-ranging trial for GB-0895 in severe asthma, and the company said going directly into Phase 3 with a single dose carries higher risk. It is testing a 300 mg subcutaneous dose every six months.
CEO Mike Nally said in May that Generate was “advancing GB-0895 in Phase 3 for severe asthma and Phase 1b for COPD.” The company also said clinical trial sites had been activated for GB-4362 and first patient dosing was expected in mid-2026; GB-5267 was expected to dose its first patient in the second half of 2026. PR Newswire
Revenue is still collaboration revenue, not product revenue. Generate recorded $7.2 million in first-quarter collaboration revenue, down from $8.8 million a year earlier; $6.5 million came under its Novartis NYSE:NVS agreement and $0.7 million from Amgen NASDAQ:AMGN.
The stock’s advance ran with a sector bid. State Street SPDR S&P Biotech ETF (NYSEARCA:XBI) closed 2.5% higher Friday and was up more than 13% in June, Barron’s reported. Mizuho healthcare sector specialist Jared Holz said XBI had “moved higher a record 12 of 13 months” and told Barron’s the sector had not traded “this consistently well in years-arguably ever.” Barron’s
Generate President and CFO Jason Silvers told Reuters at the IPO that “Machine learning provides access to tools that traditional drug discovery does not.” He also said, “this is a great time because we have a number of initiatives that require capital.” Reuters
IPOX Research Associate Lukas Muehlbauer told Reuters before the listing that “valuation will be the main focus,” and said investors would want proof that AI changes drug development because the industry had yet to see a fully AI-discovered drug win FDA approval. Reuters
U.S. markets are shut this weekend. Nasdaq regular trading runs Monday through Friday from 9:30 a.m. to 4 p.m. Eastern, and the exchange is closed Friday, July 3, for Independence Day observed; that leaves four regular sessions for GENB to hold the $16 level.
